Two Sigma Advisers LP Purchases 158,400 Shares of The Chemours Company (NYSE:CC)

Two Sigma Advisers LP raised its stake in The Chemours Company (NYSE:CC - Free Report) by 31.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 661,500 shares of the specialty chemicals company's stock after buying an additional 158,400 shares during the period. Two Sigma Advisers LP owned about 0.44% of Chemours worth $11,179,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CC. Norges Bank bought a new stake in shares of Chemours in the 4th quarter valued at about $30,702,000. Bank of Montreal Can raised its stake in Chemours by 1,496.4% during the 4th quarter. Bank of Montreal Can now owns 953,240 shares of the specialty chemicals company's stock worth $16,110,000 after buying an additional 893,530 shares during the period. Ameriprise Financial Inc. raised its stake in Chemours by 23.8% during the 4th quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock worth $73,907,000 after buying an additional 839,849 shares during the period. Millennium Management LLC raised its stake in Chemours by 44.6% during the 4th quarter. Millennium Management LLC now owns 2,507,262 shares of the specialty chemicals company's stock worth $42,373,000 after buying an additional 773,537 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Chemours by 141.5% in the fourth quarter. Invesco Ltd. now owns 1,020,001 shares of the specialty chemicals company's stock worth $17,238,000 after purchasing an additional 597,638 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Price Performance

NYSE CC traded down $0.32 during trading hours on Wednesday, reaching $10.30. 606,493 shares of the stock traded hands, compared to its average volume of 2,093,252. The company has a market cap of $1.54 billion, a price-to-earnings ratio of 18.08 and a beta of 1.76. The stock has a 50 day simple moving average of $11.80 and a two-hundred day simple moving average of $15.85. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The Chemours Company has a 1 year low of $9.33 and a 1 year high of $26.98.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm's revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 earnings per share. On average, analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's payout ratio is presently 175.00%.

Analyst Ratings Changes

Several analysts have recently commented on CC shares. Morgan Stanley lowered their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. UBS Group reduced their price objective on Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wall Street Zen lowered Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Royal Bank of Canada cut their price target on Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Finally, Truist Financial dropped their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $17.22.

Insider Buying and Selling

In other news, CFO Shane Hostetter acquired 4,450 shares of the business's stock in a transaction on Monday, May 19th. The shares were acquired at an average cost of $11.28 per share, with a total value of $50,196.00. Following the transaction, the chief financial officer now owns 59,694 shares in the company, valued at $673,348.32. The trade was a 8.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.34% of the stock is owned by insiders.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.